Abciximab
Nabumetone may increase the anticoagulant activities of Abciximab.
Abiraterone
The serum concentration of Nabumetone can be increased when it is combined with Abiraterone.
Acebutolol
Nabumetone may decrease the antihypertensive activities of Acebutolol.
Advertisement
Aceclofenac
The risk or severity of adverse effects can be increased when Aceclofenac is combined with Nabumetone.
Acemetacin
The risk or severity of adverse effects can be increased when Nabumetone is combined with Acemetacin.
Acenocoumarol
Nabumetone may increase the anticoagulant activities of Acenocoumarol.
Advertisement
Acetyl salicylate
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Nabumetone.
Aclarubicin
Nabumetone may decrease the excretion rate of Aclarubicin which could result in a higher serum level.
Adapalene
The risk or severity of adverse effects can be increased when Adapalene is combined with Nabumetone.
Advertisement
Alclometasone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Alclometasone.
Aldosterone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Aldosterone.
Alendronate
The risk or severity of adverse effects can be increased when Nabumetone is combined with Alendronic acid.
Alendronic acid
The risk or severity of adverse effects can be increased when Nabumetone is combined with Alendronic acid.
Aliskiren
Nabumetone may decrease the antihypertensive activities of Aliskiren.
Alminoprofen
The risk or severity of adverse effects can be increased when Alminoprofen is combined with Nabumetone.
Alprenolol
Nabumetone may decrease the antihypertensive activities of Alprenolol.
Alprostadil
The therapeutic efficacy of Alprostadil can be decreased when used in combination with Nabumetone.
Amcinonide
The risk or severity of adverse effects can be increased when Nabumetone is combined with Amcinonide.
Amikacin
Nabumetone may decrease the excretion rate of Amikacin which could result in a higher serum level.
Amiloride
Nabumetone may decrease the antihypertensive activities of Amiloride.
Ancrod
Nabumetone may increase the anticoagulant activities of Ancrod.
Androstenedione
The risk or severity of adverse effects can be increased when Nabumetone is combined with Androstenedione.
Anhydrous Tacrolimus
Nabumetone may increase the nephrotoxic activities of Tacrolimus.
Antipyrine
The risk or severity of adverse effects can be increased when Antipyrine is combined with Nabumetone.
Antithrombin III
Nabumetone may increase the anticoagulant activities of Antithrombin III human.
Antithrombin III, Human
Nabumetone may increase the anticoagulant activities of Antithrombin III human.
Apazone
The risk or severity of adverse effects can be increased when Azapropazone is combined with Nabumetone.
Apixaban
Nabumetone may increase the anticoagulant activities of Apixaban.
Apremilast
The risk or severity of adverse effects can be increased when Apremilast is combined with Nabumetone.
Arbekacin
Nabumetone may decrease the excretion rate of Arbekacin which could result in a higher serum level.
Ardeparin
Nabumetone may increase the anticoagulant activities of Ardeparin.
Argatroban
Nabumetone may increase the anticoagulant activities of Argatroban.
Argatroban Anhydrous
Nabumetone may increase the anticoagulant activities of Argatroban.
Aspirin
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Nabumetone.
Atenolol
Nabumetone may decrease the antihypertensive activities of Atenolol.
Azelastine
The risk or severity of adverse effects can be increased when Azelastine is combined with Nabumetone.
azficel-T
The risk or severity of adverse effects can be increased when Nabumetone is combined with Azficel-T.
Azilsartan
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nabumetone.
Azilsartan kamedoxomil
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nabumetone.
Azilsartan Medoxomil
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nabumetone.
Azithromycin
The metabolism of Nabumetone can be decreased when combined with Azithromycin.
Azosemide
The therapeutic efficacy of Azosemide can be decreased when used in combination with Nabumetone.
Balsalazide
The risk or severity of adverse effects can be increased when Balsalazide is combined with Nabumetone.
Becaplermin
Nabumetone may increase the anticoagulant activities of Becaplermin.
Beclomethasone Dipropionate
The risk or severity of adverse effects can be increased when Nabumetone is combined with Beclomethasone dipropionate.
Benazepril
The risk or severity of adverse effects can be increased when Nabumetone is combined with Benazepril.
Bendroflumethiazide
The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Nabumetone.
Benzydamine
The risk or severity of adverse effects can be increased when Benzydamine is combined with Nabumetone.
Betamethasone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Betamethasone.
Betaxolol
Nabumetone may decrease the antihypertensive activities of Betaxolol.
Betrixaban
The risk or severity of bleeding can be increased when Betrixaban is combined with Nabumetone.
Bimatoprost
The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Nabumetone.
Bisoprolol
Nabumetone may decrease the antihypertensive activities of Bisoprolol.
Bivalirudin
Nabumetone may increase the anticoagulant activities of Bivalirudin.
Bopindolol
Nabumetone may decrease the antihypertensive activities of Bopindolol.
Bortezomib
The metabolism of Nabumetone can be decreased when combined with Bortezomib.
Bromfenac
The risk or severity of adverse effects can be increased when Bromfenac is combined with Nabumetone.
Budesonide
The risk or severity of adverse effects can be increased when Nabumetone is combined with Budesonide.
Bufexamac
The risk or severity of adverse effects can be increased when Bufexamac is combined with Nabumetone.
Bumetanide
The therapeutic efficacy of Bumetanide can be decreased when used in combination with Nabumetone.
Bupranolol
Nabumetone may decrease the antihypertensive activities of Bupranolol.
Caffeine
The metabolism of Nabumetone can be decreased when combined with Caffeine.
Candesartan
The risk or severity of adverse effects can be increased when Candesartan is combined with Nabumetone.
Candesartan Cilexetil
The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Nabumetone.
Captopril
The risk or severity of adverse effects can be increased when Nabumetone is combined with Captopril.
Carboprost
The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Nabumetone.
Carboprost Tromethamine
The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Nabumetone.
Carprofen
The risk or severity of adverse effects can be increased when Carprofen is combined with Nabumetone.
Carteolol
Nabumetone may decrease the antihypertensive activities of Carteolol.
Carvedilol
Nabumetone may decrease the antihypertensive activities of Carvedilol.
Celecoxib
The risk or severity of adverse effects can be increased when Nabumetone is combined with Celecoxib.
Celiprolol
Nabumetone may decrease the antihypertensive activities of Celiprolol.
Certoparin
Nabumetone may increase the anticoagulant activities of Certoparin.
Chloroquine
The risk or severity of adverse effects can be increased when Chloroquine is combined with Nabumetone.
Chlorothiazide
The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nabumetone.
Chlorotrianisene
Nabumetone may increase the thrombogenic activities of Chlorotrianisene.
Chlorthalidone
The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Nabumetone.
Cholestyramine Resin
Cholestyramine can cause a decrease in the absorption of Nabumetone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Choline Magnesium Trisalicyclate
The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Nabumetone.
Ciclesonide
The risk or severity of adverse effects can be increased when Nabumetone is combined with Ciclesonide.
Cilazapril
The risk or severity of adverse effects can be increased when Nabumetone is combined with Cilazapril.
Cinoxacin
Nabumetone may increase the neuroexcitatory activities of Cinoxacin.
Citalopram
Citalopram may increase the antiplatelet activities of Nabumetone.
Citric Acid
Nabumetone may increase the anticoagulant activities of Citric Acid.
Citric Acid, Anhydrous
Nabumetone may increase the anticoagulant activities of Citric Acid.
Clobetasol
The risk or severity of adverse effects can be increased when Nabumetone is combined with Clobetasol.
Clobetasol Propionate
The risk or severity of adverse effects can be increased when Nabumetone is combined with Clobetasol propionate.
Clobetasone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Clobetasone.
Clocortolone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Clocortolone.
Clodronic Acid
The risk or severity of adverse effects can be increased when Nabumetone is combined with Clodronic Acid.
Clonixin
The risk or severity of adverse effects can be increased when Clonixin is combined with Nabumetone.
Clotrimazole
The metabolism of Nabumetone can be decreased when combined with Clotrimazole.
Colesevelam
Colesevelam can cause a decrease in the absorption of Nabumetone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Colestipol
Colestipol can cause a decrease in the absorption of Nabumetone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cortisone Acetate
The risk or severity of adverse effects can be increased when Nabumetone is combined with Cortisone acetate.
Curcumin
The risk or severity of adverse effects can be increased when Curcumin is combined with Nabumetone.
Cyclopenthiazide
The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Nabumetone.
Cyclosporine
Nabumetone may increase the nephrotoxic activities of Cyclosporine.
Cyproterone Acetate
The serum concentration of Nabumetone can be decreased when it is combined with Cyproterone acetate.
Dabigatran Etexilate
Nabumetone may increase the anticoagulant activities of Dabigatran etexilate.
Dalteparin
Nabumetone may increase the anticoagulant activities of Dalteparin.
Danaparoid
Nabumetone may increase the anticoagulant activities of Danaparoid.
Daunorubicin
Nabumetone may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Deferasirox
The risk or severity of adverse effects can be increased when Nabumetone is combined with Deferasirox.
Deflazacort
The risk or severity of adverse effects can be increased when Nabumetone is combined with Deflazacort.
Desirudin
Nabumetone may increase the anticoagulant activities of Desirudin.
Desmopressin
The risk or severity of adverse effects can be increased when Nabumetone is combined with Desmopressin.
Desonide
The risk or severity of adverse effects can be increased when Nabumetone is combined with Desonide.
Desoximetasone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Desoximetasone.
Desoxycorticosterone acetate
The risk or severity of adverse effects can be increased when Nabumetone is combined with Desoxycorticosterone acetate.
Desoxycorticosterone Pivalate
The risk or severity of adverse effects can be increased when Nabumetone is combined with Desoxycorticosterone Pivalate.
Desvenlafaxine
Desvenlafaxine may increase the antiplatelet activities of Nabumetone.
Dexamethasone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Dexamethasone.
Dexketoprofen
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Nabumetone.
Dextran
Nabumetone may increase the anticoagulant activities of Dextran.
Dextran 40
Nabumetone may increase the anticoagulant activities of Dextran 40.
Dextran 70
Nabumetone may increase the anticoagulant activities of Dextran 70.
Dextran 75
Nabumetone may increase the anticoagulant activities of Dextran 75.
Diclofenac
The risk or severity of adverse effects can be increased when Diclofenac is combined with Nabumetone.
Dicumarol
Nabumetone may increase the anticoagulant activities of Dicoumarol.
Dienestrol
Nabumetone may increase the thrombogenic activities of Dienestrol.
Diethylstilbestrol
Nabumetone may increase the thrombogenic activities of Diethylstilbestrol.
Diflorasone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Diflorasone.
Diflucortolone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Difluocortolone.
Diflunisal
The risk or severity of adverse effects can be increased when Diflunisal is combined with Nabumetone.
Difluprednate
The risk or severity of adverse effects can be increased when Nabumetone is combined with Difluprednate.
Digoxin
The serum concentration of Digoxin can be increased when it is combined with Nabumetone.
Dihydrostreptomycin
Nabumetone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.
Dinoprost
The therapeutic efficacy of Dinoprost can be decreased when used in combination with Nabumetone.
Dinoprost Tromethamine
The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Nabumetone.
Dinoprostone
The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Nabumetone.
Dipyrone
The risk or severity of adverse effects can be increased when Metamizole is combined with Nabumetone.
Dothiepin
The metabolism of Nabumetone can be decreased when combined with Dosulepin.
Doxorubicin
Nabumetone may decrease the excretion rate of Doxorubicin which could result in a higher serum level.
Doxorubicin Hydrochloride
Nabumetone may decrease the excretion rate of Doxorubicin which could result in a higher serum level.
Drospirenone
Nabumetone may increase the hyperkalemic activities of Drospirenone.
Droxicam
The risk or severity of adverse effects can be increased when Droxicam is combined with Nabumetone.
Duloxetine
Duloxetine may increase the antiplatelet activities of Nabumetone.
Edetic Acid
Nabumetone may increase the anticoagulant activities of Edetic Acid.
Edoxaban
Nabumetone may increase the anticoagulant activities of Edoxaban.
Enalapril
The risk or severity of adverse effects can be increased when Nabumetone is combined with Enalapril.
Enalaprilat
The risk or severity of adverse effects can be increased when Nabumetone is combined with Enalaprilat.
Enalaprilat Anhydrous
The risk or severity of adverse effects can be increased when Nabumetone is combined with Enalaprilat.
Enoxacin
Nabumetone may increase the neuroexcitatory activities of Enoxacin.
Enoxaparin
Nabumetone may increase the anticoagulant activities of Enoxaparin.
Enoxaparin sodium
Nabumetone may increase the anticoagulant activities of Enoxaparin.
Epirubicin
Nabumetone may decrease the excretion rate of Epirubicin which could result in a higher serum level.
Eplerenone
Nabumetone may decrease the antihypertensive activities of Eplerenone.
Epoprostenol
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Nabumetone.
Eprosartan
The risk or severity of adverse effects can be increased when Eprosartan is combined with Nabumetone.
Equol, (-)-
Nabumetone may increase the thrombogenic activities of Equol.
Escitalopram
Escitalopram may increase the antiplatelet activities of Nabumetone.
Esmolol
Nabumetone may decrease the antihypertensive activities of Esmolol.
Estradiol
Nabumetone may increase the thrombogenic activities of Estradiol.
Estradiol acetate
Nabumetone may increase the thrombogenic activities of Estradiol acetate.
Estradiol Cypionate
Nabumetone may increase the thrombogenic activities of Estradiol cypionate.
Estradiol Valerate
Nabumetone may increase the thrombogenic activities of Estradiol valerate.
Estriol
Nabumetone may increase the thrombogenic activities of Estriol.
Estrogens, Conjugated (USP)
Nabumetone may increase the thrombogenic activities of Conjugated estrogens.
Estrogens, Esterified (USP)
Nabumetone may increase the thrombogenic activities of Estrogens, esterified.
Estrone
Nabumetone may increase the thrombogenic activities of Estrone.
Etanercept
The risk or severity of adverse effects can be increased when Etanercept is combined with Nabumetone.
Ethacrynate
The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Nabumetone.
Ethacrynic Acid
The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Nabumetone.
Ethinyl Estradiol
Nabumetone may increase the thrombogenic activities of Ethinyl Estradiol.
Ethylenediaminetetraacetate
Nabumetone may increase the anticoagulant activities of Edetic Acid.
Etidronate
The risk or severity of adverse effects can be increased when Nabumetone is combined with Etidronic acid.
Etidronic Acid
The risk or severity of adverse effects can be increased when Nabumetone is combined with Etidronic acid.
Etodolac
The risk or severity of adverse effects can be increased when Nabumetone is combined with Etodolac.
Etofenamate
The risk or severity of adverse effects can be increased when Etofenamate is combined with Nabumetone.
Etoricoxib
The risk or severity of adverse effects can be increased when Nabumetone is combined with Etoricoxib.
Evening primrose oil
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Nabumetone.
Felbinac
The risk or severity of adverse effects can be increased when Felbinac is combined with Nabumetone.
Fenbufen
The risk or severity of adverse effects can be increased when Fenbufen is combined with Nabumetone.
Fenoprofen
The risk or severity of adverse effects can be increased when Fenoprofen is combined with Nabumetone.
Ferulic Acid
The risk or severity of adverse effects can be increased when Ferulic acid is combined with Nabumetone.
Fleroxacin
Nabumetone may increase the neuroexcitatory activities of Fleroxacin.
Floctafenine
The risk or severity of adverse effects can be increased when Floctafenine is combined with Nabumetone.
Fludrocortisone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Fludrocortisone.
Fluindione
Nabumetone may increase the anticoagulant activities of Fluindione.
Flumequine
Nabumetone may increase the neuroexcitatory activities of Flumequine.
Flumethasone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Flumethasone.
Flunisolide
The risk or severity of adverse effects can be increased when Nabumetone is combined with Flunisolide.
Flunisolide Anhydrous (obsolete)
The risk or severity of adverse effects can be increased when Nabumetone is combined with Flunisolide.
Fluocinolone Acetonide
The risk or severity of adverse effects can be increased when Nabumetone is combined with Fluocinolone Acetonide.
Fluocinonide
The risk or severity of adverse effects can be increased when Nabumetone is combined with Fluocinonide.
Fluocortolone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Fluocortolone.
Fluorometholone
The risk or severity of adverse effects can be increased when Fluorometholone is combined with Nabumetone.
Fluoxetine
Fluoxetine may increase the antiplatelet activities of Nabumetone.
FLUPREDNIDENE
The risk or severity of adverse effects can be increased when Nabumetone is combined with Fluprednidene.
Fluprednisolone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Fluprednisolone.
Flurandrenolide
The risk or severity of adverse effects can be increased when Nabumetone is combined with Flurandrenolide.
Flurbiprofen
The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Nabumetone.
Fluticasone Furoate
The risk or severity of adverse effects can be increased when Nabumetone is combined with Fluticasone furoate.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Nabumetone is combined with Fluticasone propionate.
Fluvoxamine
The metabolism of Nabumetone can be decreased when combined with Fluvoxamine.
Folate
The therapeutic efficacy of Folic Acid can be decreased when used in combination with Nabumetone.
Folic Acid
The therapeutic efficacy of Folic Acid can be decreased when used in combination with Nabumetone.
Fondaparinux
Nabumetone may increase the anticoagulant activities of Fondaparinux.
Fondaparinux sodium
Nabumetone may increase the anticoagulant activities of Fondaparinux sodium.
Formestane
The risk or severity of adverse effects can be increased when Nabumetone is combined with Formestane.
Fosinopril
The risk or severity of adverse effects can be increased when Nabumetone is combined with Fosinopril.
Framycetin
Nabumetone may decrease the excretion rate of Framycetin which could result in a higher serum level.
Furosemide
The therapeutic efficacy of Furosemide can be decreased when used in combination with Nabumetone.
Gatifloxacin
Nabumetone may increase the neuroexcitatory activities of Gatifloxacin.
Gatifloxacin Anhydrous
Nabumetone may increase the neuroexcitatory activities of Gatifloxacin.
Gemeprost
The therapeutic efficacy of Gemeprost can be decreased when used in combination with Nabumetone.
Gemifloxacin
Nabumetone may increase the neuroexcitatory activities of Gemifloxacin.
Gemifloxacin Mesylate
Nabumetone may increase the neuroexcitatory activities of Gemifloxacin.
Genistein
Nabumetone may increase the thrombogenic activities of Genistein.
Gentamicin
Nabumetone may decrease the excretion rate of Gentamicin which could result in a higher serum level.
Grepafloxacin
Nabumetone may increase the neuroexcitatory activities of Grepafloxacin.
Halcinonide
The risk or severity of adverse effects can be increased when Nabumetone is combined with Halcinonide.
Halobetasol
The risk or severity of adverse effects can be increased when Nabumetone is combined with Ulobetasol.
Haloperidol
The risk or severity of adverse effects can be increased when Nabumetone is combined with Haloperidol.
Heparin
Nabumetone may increase the anticoagulant activities of Heparin.
Hydralazine
Nabumetone may decrease the antihypertensive activities of Hydralazine.
Hydrochlorothiazide
The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nabumetone.
Hydrocortisone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Hydrocortisone.
Hydroflumethiazide
The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Nabumetone.
Ibandronate
The risk or severity of adverse effects can be increased when Nabumetone is combined with Ibandronate.
Ibandronic Acid
The risk or severity of adverse effects can be increased when Nabumetone is combined with Ibandronate.
Ibuprofen
The risk or severity of adverse effects can be increased when Ibuprofen is combined with Nabumetone.
Icatibant
The risk or severity of adverse effects can be increased when Icatibant is combined with Nabumetone.
Idarubicin
Nabumetone may decrease the excretion rate of Idarubicin which could result in a higher serum level.
Iloprost
The therapeutic efficacy of Iloprost can be decreased when used in combination with Nabumetone.
Imidapril
The risk or severity of adverse effects can be increased when Nabumetone is combined with Imidapril.
Indapamide
The therapeutic efficacy of Indapamide can be decreased when used in combination with Nabumetone.
Indobufen
The risk or severity of adverse effects can be increased when Indobufen is combined with Nabumetone.
Indomethacin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Nabumetone.
Irbesartan
The risk or severity of adverse effects can be increased when Irbesartan is combined with Nabumetone.
Kanamycin
Nabumetone may decrease the excretion rate of Kanamycin which could result in a higher serum level.
kanamycin A
Nabumetone may decrease the excretion rate of Kanamycin which could result in a higher serum level.
Kebuzone
The risk or severity of adverse effects can be increased when Kebuzone is combined with Nabumetone.
Ketoprofen
The risk or severity of adverse effects can be increased when Ketoprofen is combined with Nabumetone.
Ketorolac
The risk or severity of adverse effects can be increased when Ketorolac is combined with Nabumetone.
Labetalol
Nabumetone may decrease the antihypertensive activities of Labetalol.
Latanoprost
The therapeutic efficacy of Latanoprost can be decreased when used in combination with Nabumetone.
Latanoprostene Bunod
The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Nabumetone.
Leflunomide
The risk or severity of adverse effects can be increased when Leflunomide is combined with Nabumetone.
Lepirudin
Nabumetone may increase the anticoagulant activities of Lepirudin.
Levobunolol
Nabumetone may decrease the antihypertensive activities of Levobunolol.
Levofloxacin
Nabumetone may increase the neuroexcitatory activities of Levofloxacin.
Levofloxacin Anhydrous
Nabumetone may increase the neuroexcitatory activities of Levofloxacin.
Levomilnacipran
Levomilnacipran may increase the antiplatelet activities of Nabumetone.
Lidocaine
The metabolism of Nabumetone can be decreased when combined with Lidocaine.
Limonene, (+)-
The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Nabumetone.
Lisinopril
The risk or severity of adverse effects can be increased when Nabumetone is combined with Lisinopril.
Lisinopril Anhydrous
The risk or severity of adverse effects can be increased when Nabumetone is combined with Lisinopril.
Lithium
The serum concentration of Lithium can be increased when it is combined with Nabumetone.
Lithium Cation
The serum concentration of Lithium can be increased when it is combined with Nabumetone.
Lornoxicam
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Nabumetone.
Losartan
The risk or severity of adverse effects can be increased when Losartan is combined with Nabumetone.
Loteprednol
The risk or severity of adverse effects can be increased when Nabumetone is combined with Loteprednol.
Loxoprofen
The risk or severity of adverse effects can be increased when Loxoprofen is combined with Nabumetone.
Lubiprostone
The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Nabumetone.
Magnesium Salicylate
The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Nabumetone.
Masoprocol
The risk or severity of adverse effects can be increased when Masoprocol is combined with Nabumetone.
Meclofenamate
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Nabumetone.
Meclofenamic Acid
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Nabumetone.
Medronate
The risk or severity of adverse effects can be increased when Nabumetone is combined with Technetium Tc-99m medronate.
Medrysone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Medrysone.
Mefenamic Acid
The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Nabumetone.
Meloxicam
The risk or severity of adverse effects can be increased when Meloxicam is combined with Nabumetone.
Mesalamine
The risk or severity of adverse effects can be increased when Mesalazine is combined with Nabumetone.
Mestranol
Nabumetone may increase the thrombogenic activities of Mestranol.
Methotrexate
The serum concentration of Methotrexate can be increased when it is combined with Nabumetone.
Methyclothiazide
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nabumetone.
Methylprednisolone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Methylprednisolone.
Metipranolol
Nabumetone may decrease the antihypertensive activities of Metipranolol.
Metolazone
The therapeutic efficacy of Metolazone can be decreased when used in combination with Nabumetone.
Metoprolol
Nabumetone may decrease the antihypertensive activities of Metoprolol.
Metrizamide
Nabumetone may decrease the excretion rate of Metrizamide which could result in a higher serum level.
Mexiletine
The metabolism of Nabumetone can be decreased when combined with Mexiletine.
Midostaurin
The metabolism of Nabumetone can be decreased when combined with Midostaurin.
Milnacipran
Milnacipran may increase the antiplatelet activities of Nabumetone.
Misoprostol
The therapeutic efficacy of Misoprostol can be decreased when used in combination with Nabumetone.
Moexipril
The risk or severity of adverse effects can be increased when Nabumetone is combined with Moexipril.
Mometasone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Mometasone.
Morniflumate
The risk or severity of adverse effects can be increased when Morniflumate is combined with Nabumetone.
MYCOPHENOLATE
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Nabumetone.
Mycophenolate Mofetil
The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Nabumetone.
Mycophenolic Acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Nabumetone.
Nadolol
Nabumetone may decrease the antihypertensive activities of Nadolol.
Nadroparin
Nabumetone may increase the anticoagulant activities of Nadroparin.
Naftifine
The risk or severity of adverse effects can be increased when Naftifine is combined with Nabumetone.
Nalidixic Acid
Nabumetone may increase the neuroexcitatory activities of Nalidixic Acid.
Naproxen
The risk or severity of adverse effects can be increased when Naproxen is combined with Nabumetone.
Nebivolol
Nabumetone may decrease the antihypertensive activities of Nebivolol.
Nefazodone
Nefazodone may increase the antiplatelet activities of Nabumetone.
Neomycin
Nabumetone may decrease the excretion rate of Neomycin which could result in a higher serum level.
Nepafenac
The risk or severity of adverse effects can be increased when Nepafenac is combined with Nabumetone.
Netilmicin
Nabumetone may decrease the excretion rate of Netilmicin which could result in a higher serum level.
Nevirapine
The metabolism of Nabumetone can be decreased when combined with Nevirapine.
Niflumic Acid
The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Nabumetone.
Nimesulide
The risk or severity of adverse effects can be increased when Nimesulide is combined with Nabumetone.
Norfloxacin
Nabumetone may increase the neuroexcitatory activities of Norfloxacin.
Oenothera biennis seed extract
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Nabumetone.
Olmesartan
The risk or severity of adverse effects can be increased when Olmesartan is combined with Nabumetone.
Olopatadine
The risk or severity of adverse effects can be increased when Olopatadine is combined with Nabumetone.
Olsalazine
The risk or severity of adverse effects can be increased when Olsalazine is combined with Nabumetone.
Omacetaxine Mepesuccinate
The risk or severity of bleeding can be increased when Nabumetone is combined with Omacetaxine mepesuccinate.
Osimertinib
The serum concentration of Nabumetone can be decreased when it is combined with Osimertinib.
Oxaprozin
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Nabumetone.
Oxprenolol
Nabumetone may decrease the antihypertensive activities of Oxprenolol.
Oxyphenbutazone
The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Nabumetone.
Pamidronate
The risk or severity of adverse effects can be increased when Nabumetone is combined with Pamidronate.
Pamidronic Acid
The risk or severity of adverse effects can be increased when Nabumetone is combined with Pamidronate.
Paramethasone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Paramethasone.
Parecoxib
The risk or severity of adverse effects can be increased when Nabumetone is combined with Parecoxib.
Paromomycin
Nabumetone may decrease the excretion rate of Paromomycin which could result in a higher serum level.
Paroxetine
Paroxetine may increase the antiplatelet activities of Nabumetone.
Parthenolide
The risk or severity of adverse effects can be increased when Parthenolide is combined with Nabumetone.
Pefloxacin
Nabumetone may increase the neuroexcitatory activities of Pefloxacin.
Peginterferon Alfa-2b
The serum concentration of Nabumetone can be increased when it is combined with Peginterferon alfa-2b.
Penbutolol
Nabumetone may decrease the antihypertensive activities of Penbutolol.
Pentaerythritol Tetranitrate
Nabumetone may increase the anticoagulant activities of Pentaerythritol Tetranitrate.
Pentosan Polysulfate
Nabumetone may increase the anticoagulant activities of Pentosan Polysulfate.
Perindopril
The risk or severity of adverse effects can be increased when Nabumetone is combined with Perindopril.
Phenindione
Nabumetone may increase the anticoagulant activities of Phenindione.
Phenprocoumon
Nabumetone may increase the anticoagulant activities of Phenprocoumon.
Phenylbutazone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Nabumetone.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nabumetone.
Pindolol
Nabumetone may decrease the antihypertensive activities of Pindolol.
Pirarubicin
Nabumetone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.
Piretanide
The therapeutic efficacy of Piretanide can be decreased when used in combination with Nabumetone.
Pirfenidone
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Nabumetone.
Piroxicam
The risk or severity of adverse effects can be increased when Piroxicam is combined with Nabumetone.
Piroxicam-Beta-Cyclodextrin
The risk or severity of adverse effects can be increased when Piroxicam is combined with Nabumetone.
Plicamycin
Nabumetone may decrease the excretion rate of Plicamycin which could result in a higher serum level.
Polyestradiol Phosphate
Nabumetone may increase the thrombogenic activities of Polyestradiol phosphate.
Polythiazide
The therapeutic efficacy of Polythiazide can be decreased when used in combination with Nabumetone.
Practolol
Nabumetone may decrease the antihypertensive activities of Practolol.
Pralatrexate
The serum concentration of Pralatrexate can be increased when it is combined with Nabumetone.
Prasterone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Prasterone.
Prednicarbate
The risk or severity of adverse effects can be increased when Nabumetone is combined with Prednicarbate.
Prednisolone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Prednisolone.
Prednisone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Prednisone.
Pregnenolone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Pregnenolone.
Probenecid
The serum concentration of Nabumetone can be increased when it is combined with Probenecid.
Promestriene
Nabumetone may increase the thrombogenic activities of Promestriene.
Propranolol
Nabumetone may decrease the antihypertensive activities of Propranolol.
protein C, human
Nabumetone may increase the anticoagulant activities of Protein C.
protein S, human
Nabumetone may increase the anticoagulant activities of Protein S human.
Protocatechualdehyde
Nabumetone may increase the anticoagulant activities of Protocatechualdehyde.
Quinapril
The risk or severity of adverse effects can be increased when Nabumetone is combined with Quinapril.
Quinestrol
Nabumetone may increase the thrombogenic activities of Quinestrol.
Quinethazone
The therapeutic efficacy of Quinethazone can be decreased when used in combination with Nabumetone.
Ramipril
The risk or severity of adverse effects can be increased when Nabumetone is combined with Ramipril.
Rescinnamine
The risk or severity of adverse effects can be increased when Nabumetone is combined with Rescinnamine.
Resveratrol
The risk or severity of adverse effects can be increased when Resveratrol is combined with Nabumetone.
Reviparin
Nabumetone may increase the anticoagulant activities of Reviparin.
Reviparin sodium
Nabumetone may increase the anticoagulant activities of Reviparin.
Rimexolone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Rimexolone.
Risedronate
The risk or severity of adverse effects can be increased when Nabumetone is combined with Risedronate.
Risedronic Acid
The risk or severity of adverse effects can be increased when Nabumetone is combined with Risedronate.
Rivaroxaban
Nabumetone may increase the anticoagulant activities of Rivaroxaban.
Rofecoxib
The risk or severity of adverse effects can be increased when Nabumetone is combined with Rofecoxib.
Ropinirole
The metabolism of Nabumetone can be decreased when combined with Ropinirole.
Rosoxacin
Nabumetone may increase the neuroexcitatory activities of Rosoxacin.
Rucaparib
The metabolism of Nabumetone can be decreased when combined with Rucaparib.
Sacubitril
The risk or severity of adverse effects can be increased when Sacubitril is combined with Nabumetone.
Salicylamide
The risk or severity of adverse effects can be increased when Salicylamide is combined with Nabumetone.
Salicylic Acid
The risk or severity of adverse effects can be increased when Salicylic acid is combined with Nabumetone.
Salsalate
The risk or severity of adverse effects can be increased when Salsalate is combined with Nabumetone.
Saralasin
The risk or severity of adverse effects can be increased when Saralasin is combined with Nabumetone.
Sarilumab
Sarilumab may increase the immunosuppressive activities of Nabumetone.
Serratiopeptidase
The risk or severity of adverse effects can be increased when Serrapeptase is combined with Nabumetone.
Sertraline
Sertraline may increase the antiplatelet activities of Nabumetone.
Simeprevir
The metabolism of Nabumetone can be decreased when combined with Simeprevir.
Sisomicin
Nabumetone may decrease the excretion rate of Sisomicin which could result in a higher serum level.
Sodium Phosphate
Sodium phosphate may increase the nephrotoxic activities of Nabumetone.
Sodium Phosphate, Monobasic
Sodium phosphate may increase the nephrotoxic activities of Nabumetone.
SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
Sodium phosphate may increase the nephrotoxic activities of Nabumetone.
Sotalol
Nabumetone may decrease the antihypertensive activities of Sotalol.
Sparfloxacin
Nabumetone may increase the neuroexcitatory activities of Sparfloxacin.
Spectinomycin
Nabumetone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.
Spirapril
The risk or severity of adverse effects can be increased when Nabumetone is combined with Spirapril.
Spironolactone
Nabumetone may decrease the antihypertensive activities of Spironolactone.
Streptomycin
Nabumetone may decrease the excretion rate of Streptomycin which could result in a higher serum level.
Streptozocin
Nabumetone may decrease the excretion rate of Streptozocin which could result in a higher serum level.
Sulfasalazine
The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Nabumetone.
Sulindac
The risk or severity of adverse effects can be increased when Sulindac is combined with Nabumetone.
Suprofen
The risk or severity of adverse effects can be increased when Suprofen is combined with Nabumetone.
synthetic conjugated estrogens, A
Nabumetone may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.
synthetic conjugated estrogens, B
Nabumetone may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.
Tacrolimus
Nabumetone may increase the nephrotoxic activities of Tacrolimus.
Tafluprost
The therapeutic efficacy of Tafluprost can be decreased when used in combination with Nabumetone.
Talinolol
Nabumetone may decrease the antihypertensive activities of Talinolol.
Talniflumate
The risk or severity of adverse effects can be increased when Talniflumate is combined with Nabumetone.
Technetium Tc 99m Medronate
The risk or severity of adverse effects can be increased when Nabumetone is combined with Technetium Tc-99m medronate.
Telmisartan
The risk or severity of adverse effects can be increased when Telmisartan is combined with Nabumetone.
Temafloxacin
Nabumetone may increase the neuroexcitatory activities of Temafloxacin.
Tenofovir Disoproxil
The risk or severity of adverse effects can be increased when Nabumetone is combined with Tenofovir disoproxil.
Tenoxicam
The risk or severity of adverse effects can be increased when Tenoxicam is combined with Nabumetone.
Teriflunomide
The serum concentration of Nabumetone can be decreased when it is combined with Teriflunomide.
Theophylline
The metabolism of Nabumetone can be decreased when combined with Theophylline.
Theophylline anhydrous
The metabolism of Nabumetone can be decreased when combined with Theophylline.
Tiaprofenic Acid
The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Nabumetone.
Tibolone
Nabumetone may increase the thrombogenic activities of Tibolone.
Ticlopidine
The metabolism of Nabumetone can be decreased when combined with Ticlopidine.
Tiludronate
The risk or severity of adverse effects can be increased when Nabumetone is combined with Tiludronic acid.
Tiludronic Acid
The risk or severity of adverse effects can be increased when Nabumetone is combined with Tiludronic acid.
Timolol
Nabumetone may decrease the antihypertensive activities of Timolol.
Timolol Anhydrous
Nabumetone may decrease the antihypertensive activities of Timolol.
Tixocortol
The risk or severity of adverse effects can be increased when Nabumetone is combined with Tixocortol.
Tobramycin
Nabumetone may decrease the excretion rate of Tobramycin which could result in a higher serum level.
Tolfenamic Acid
The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Nabumetone.
Tolmetin
The risk or severity of adverse effects can be increased when Tolmetin is combined with Nabumetone.
Torsemide
The therapeutic efficacy of Torasemide can be decreased when used in combination with Nabumetone.
Trandolapril
The risk or severity of adverse effects can be increased when Nabumetone is combined with Trandolapril.
Tranilast
The risk or severity of adverse effects can be increased when Tranilast is combined with Nabumetone.
Travoprost
The therapeutic efficacy of Travoprost can be decreased when used in combination with Nabumetone.
Treprostinil
The risk or severity of adverse effects can be increased when Treprostinil is combined with Nabumetone.
Triamcinolone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Triamcinolone.
Triamterene
Nabumetone may decrease the antihypertensive activities of Triamterene.
Trichlormethiazide
The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Nabumetone.
Trovafloxacin
Nabumetone may increase the neuroexcitatory activities of Trovafloxacin.
Troxerutin
Nabumetone may increase the anticoagulant activities of Troxerutin.
UNOPROSTONE
The therapeutic efficacy of Unoprostone can be decreased when used in combination with Nabumetone.
Valdecoxib
The risk or severity of adverse effects can be increased when Nabumetone is combined with Valdecoxib.
Valrubicin
Nabumetone may decrease the excretion rate of Valrubicin which could result in a higher serum level.
Valsartan
The risk or severity of adverse effects can be increased when Valsartan is combined with Nabumetone.
Vancomycin
The serum concentration of Vancomycin can be increased when it is combined with Nabumetone.
Vemurafenib
The serum concentration of Nabumetone can be increased when it is combined with Vemurafenib.
Venlafaxine
Venlafaxine may increase the antiplatelet activities of Nabumetone.
Warfarin
Nabumetone may increase the anticoagulant activities of Warfarin.
Zileuton
The risk or severity of adverse effects can be increased when Zileuton is combined with Nabumetone.
Zofenopril
The risk or severity of adverse effects can be increased when Nabumetone is combined with Zofenopril.
Zoledronic Acid
The risk or severity of adverse effects can be increased when Nabumetone is combined with Zoledronic acid.
Zoledronic Acid Anhydrous
The risk or severity of adverse effects can be increased when Nabumetone is combined with Zoledronic acid.
Zomepirac
The risk or severity of adverse effects can be increased when Zomepirac is combined with Nabumetone.
